ANNX — Annexon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1528115 ·
Last close
$5.06
Market Cap
$959.27M
52W High
$6.58
52W Low
$4.46
ADV30
3,036,524
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,053,000 | -44,142,000 | 262,888,000 | 175,208,000 | 58,355,000 |
| Dec 2025 | 0 | — | -50,258,000 | -48,256,000 | 277,571,000 | 162,051,000 | 65,923,000 |
| Sep 2025 | 0 | — | -57,018,000 | -54,922,000 | 229,142,000 | 139,419,000 | 67,700,000 |
| Jun 2025 | 0 | — | -51,726,000 | -49,156,000 | 264,573,000 | 132,288,000 | 65,556,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-183,097,000
Investing CF
$119,488,000
Financing CF
$141,692,000
CapEx
$-143,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-961,531,000
Inventory
—
Receivables
—
ST Investments
$49,817,000
EBIT TTM
$-205,055,000
Pretax Income TTM
$-196,476,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -216,407,000 | -206,690,000 | 277,571,000 | 65,923,000 | — | -186,356,000 |
| Dec 2024 | 0 | -154,073,000 | -138,200,000 | 350,071,000 | 56,966,000 | — | -118,006,000 |
| Dec 2023 | 0 | -143,723,000 | -134,237,000 | 297,674,000 | 47,118,000 | — | -121,142,000 |
| Dec 2022 | 0 | -145,599,000 | -141,947,000 | 285,096,000 | 53,902,000 | — | -116,309,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.08
Max Pain — expiry 2026-10-16
max pain strike: $6.00 · spot: $5.06 · call oi: 2,352 · put oi: 2,667
Expected Move to 2026-10-16:
±$1.32
(26.19%) —
implied range
$3.73 –
$6.38
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | $953.12M | $15.23 | — |
| ARDX | ARDELYX, INC. | $965.62M | $3.74 | — |
| HELP | CYBIN INC. | $951.24M | $13.02 | — |
| IMMX | Immix Biopharma, Inc. | $968.90M | $13.61 | — |
| GERN | GERON CORP | $976.56M | $1.52 | — |
News headlines (Yahoo Finance, 1h cache)
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
2026-08-24 08:08 · Yahoo
Annexon (ANNX), What Is Behind Its Latest Update?
2026-08-13 18:13 · Yahoo
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
2026-08-12 11:33 · Yahoo
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
2026-08-06 12:00 · Yahoo
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
2026-07-30 20:01 · Yahoo
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
2026-07-16 23:17 · Yahoo
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
2026-07-14 20:05 · Yahoo
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-06-16 20:05 · Yahoo
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
2026-06-04 07:07 · Yahoo
Annexon, Inc. Q2 2026 Earnings Call Summary
2026-08-12 20:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.